Literature DB >> 18228185

FluBlok, a recombinant influenza vaccine.

Victor C Huber1, Jonathan A McCullers.   

Abstract

Protein Sciences Corp and UMN Pharma Inc are developing FluBlok, an injectable trivalent influenza vaccine formulation composed of recombinant influenza hemagglutinin (HA) proteins that match the HA from the three influenza isolates that currently circulate in humans (H1N1, H3N2 and B), for the potential prevention of influenza virus infection. Phase III clinical trials to compare FluBlok and a licensed trivalent influenza vaccine for immunogenicity, safety and efficacy in preventing naturally occurring influenza are ongoing.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18228185

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  10 in total

Review 1.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

Review 2.  Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults.

Authors:  Lily P H Yang
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

Review 3.  Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults.

Authors:  Manon M J Cox; Ruvim Izikson; Penny Post; Lisa Dunkle
Journal:  Ther Adv Vaccines       Date:  2015-07

4.  Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets.

Authors:  Berend Jan Bosch; Rogier Bodewes; Robert P de Vries; Joost H C M Kreijtz; Willem Bartelink; Geert van Amerongen; Guus F Rimmelzwaan; Cornelis A M de Haan; Albert D M E Osterhaus; Peter J M Rottier
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

5.  Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications.

Authors:  Victor C Huber; Ville Peltola; Amy R Iverson; Jonathan A McCullers
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

6.  A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.

Authors:  Victor C Huber; Paul G Thomas; Jonathan A McCullers
Journal:  Vaccine       Date:  2009-01-07       Impact factor: 3.641

7.  Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19.

Authors:  Jiao Tong; Chenxi Zhu; Hanyu Lai; Chunchao Feng; Dapeng Zhou
Journal:  Vaccines (Basel)       Date:  2021-03-22

Review 8.  FluBlok, a recombinant hemagglutinin influenza vaccine.

Authors:  Manon M J Cox; Peter A Patriarca; John Treanor
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380

9.  Topoisomerase II Inhibitors Can Enhance Baculovirus-Mediated Gene Expression in Mammalian Cells through the DNA Damage Response.

Authors:  Ming-Kun Liu; Jhe-Jhih Lin; Chung-Yung Chen; Szu-Cheng Kuo; Yu-Ming Wang; Hong-Lin Chan; Tzong Yuan Wu
Journal:  Int J Mol Sci       Date:  2016-06-14       Impact factor: 5.923

10.  Las vacunas de la gripe basadas en las partículas virus-like obtenidas mediante sistemas de expresión génica en células de insectos.

Authors:  J Reina
Journal:  Vacunas       Date:  2012-11-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.